These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 2336876)

  • 1. Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus.
    Collins PL; Purcell RH; London WT; Lawrence LA; Chanock RM; Murphy BR
    Vaccine; 1990 Apr; 8(2):164-8. PubMed ID: 2336876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV.
    Crowe JE; Collins PL; London WT; Chanock RM; Murphy BR
    Vaccine; 1993 Nov; 11(14):1395-404. PubMed ID: 8310760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.
    Connors M; Collins PL; Firestone CY; Sotnikov AV; Waitze A; Davis AR; Hung PP; Chanock RM; Murphy BR
    Vaccine; 1992; 10(7):475-84. PubMed ID: 1609551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosuppression of the antibody response to respiratory syncytial virus (RSV) by pre-existing serum antibodies: partial prevention by topical infection of the respiratory tract with vaccinia virus-RSV recombinants.
    Murphy BR; Collins PL; Lawrence L; Zubak J; Chanock RM; Prince GA
    J Gen Virol; 1989 Aug; 70 ( Pt 8)():2185-90. PubMed ID: 2671259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies.
    Connors M; Kulkarni AB; Collins PL; Firestone CY; Holmes KL; Morse HC; Murphy BR
    J Virol; 1992 Feb; 66(2):1277-81. PubMed ID: 1731105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA.
    Wyatt LS; Whitehead SS; Venanzi KA; Murphy BR; Moss B
    Vaccine; 1999 Oct; 18(5-6):392-7. PubMed ID: 10519927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation in non-human primates of the safety, immunogenicity and efficacy of recombinant vaccinia viruses expressing the F or G glycoprotein of respiratory syncytial virus.
    Olmsted RA; Buller RM; Collins PL; London WT; Beeler JA; Prince GA; Chanock RM; Murphy BR
    Vaccine; 1988 Dec; 6(6):519-24. PubMed ID: 3072795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses.
    Murphy BR; Olmsted RA; Collins PL; Chanock RM; Prince GA
    J Virol; 1988 Oct; 62(10):3907-10. PubMed ID: 3047432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus.
    Stott EJ; Taylor G; Ball LA; Anderson K; Young KK; King AM; Wertz GW
    J Virol; 1987 Dec; 61(12):3855-61. PubMed ID: 3316707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity.
    Olmsted RA; Elango N; Prince GA; Murphy BR; Johnson PR; Moss B; Chanock RM; Collins PL
    Proc Natl Acad Sci U S A; 1986 Oct; 83(19):7462-6. PubMed ID: 3532115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
    Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived.
    Connors M; Collins PL; Firestone CY; Murphy BR
    J Virol; 1991 Mar; 65(3):1634-7. PubMed ID: 1995956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity.
    Johnson PR; Olmsted RA; Prince GA; Murphy BR; Alling DW; Walsh EE; Collins PL
    J Virol; 1987 Oct; 61(10):3163-6. PubMed ID: 3305988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.
    Kahn JS; Roberts A; Weibel C; Buonocore L; Rose JK
    J Virol; 2001 Nov; 75(22):11079-87. PubMed ID: 11602747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.
    Green CA; Scarselli E; Sande CJ; Thompson AJ; de Lara CM; Taylor KS; Haworth K; Del Sorbo M; Angus B; Siani L; Di Marco S; Traboni C; Folgori A; Colloca S; Capone S; Vitelli A; Cortese R; Klenerman P; Nicosia A; Pollard AJ
    Sci Transl Med; 2015 Aug; 7(300):300ra126. PubMed ID: 26268313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation and characterization of a chimpanzee monoclonal antibody to the G glycoprotein of human respiratory syncytial virus.
    Crowe JE; Cheung PY; Wallace EF; Chanock RM; Larrick JW; Murphy BR; Fry K
    Clin Diagn Lab Immunol; 1994 Nov; 1(6):701-6. PubMed ID: 8556524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease.
    Murphy BR; Sotnikov A; Paradiso PR; Hildreth SW; Jenson AB; Baggs RB; Lawrence L; Zubak JJ; Chanock RM; Beeler JA
    Vaccine; 1989 Dec; 7(6):533-40. PubMed ID: 2692334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenovirus vectored vaccines.
    Natuk RJ; Davis AR; Chanda PK; Lubeck MD; Chengalvala M; Murthy SC; Wade MS; Dheer SK; Bhat BM; Murthy KK
    Dev Biol Stand; 1994; 82():71-7. PubMed ID: 7958485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates.
    Whitehead SS; Hill MG; Firestone CY; St Claire M; Elkins WR; Murphy BR; Collins PL
    J Virol; 1999 Dec; 73(12):9773-80. PubMed ID: 10559287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccine.
    Buchholz UJ; Granzow H; Schuldt K; Whitehead SS; Murphy BR; Collins PL
    J Virol; 2000 Feb; 74(3):1187-99. PubMed ID: 10627529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.